FHTX 8-K SEC Filing Analysis

Latest settled — T+20d

FHTX ▼ -13.33% at T+20d

NEUTRAL call ✗ call lost -13.33% · α vs SPY -16.47% · entry $4.20 → $3.64

Next anchor: T+60d in 8w

Currently $3.87 · -7.86% from $4.20 entry

Entry anchored
May 7, 2026
via day open

T+1d

+5.71%

call +5.71% · α +4.88%

$4.44

settled 5w ago

T+5d

-0.71%

call -0.71% · α -2.22%

$4.17

settled 27d ago

T+20d

-13.33%

call -13.33% · α -16.47%

$3.64

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8M), and EPS of -$0.29 (vs consensus -$0.28, a slight miss). Cash stood at $183.6M, extended into H1 2028. Pipeline advances remain on track, with Phase 1 FHD-909 trial progressing and selective CBP/EP300 degraders approaching IND-enabling studies.

Actionable Insight

Monitor upcoming IND filings for CBP (FHT-171) and EP300 degraders in 2027 and Phase 1 efficacy data for FHD-909 as key catalysts. Cash runway into H1 2028 reduces near-term dilution risk.

Key Facts

Collaboration revenue $3.3M for Q1 2026, down from $6.0M YoY due to timing of work under Lilly agreement
Net loss $19.9M vs $18.8M YoY; EPS -$0.29 vs -$0.30 YoY
Cash, cash equivalents and marketable securities $183.6M as of March 31, 2026, providing runway into H1 2028
FHD-909 Phase 1 dose-escalation trial on track; IND-enabling studies for CBP and EP300 degraders expected in 2026 with INDs in 2027
Selected preclinical data presented at AACR 2026 showing combination activity with anti-PD-1 and KRAS inhibitors

Financial Impact

No material financial impact; company remains pre-revenue with collaboration revenue variability

revenuenetLosseps

Risk Factors

Clinical trial delays or failures, particularly for FHD-909
Dependence on Lilly collaboration for revenue and development
Need for additional capital beyond 2028 runway

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

94% bullish (16 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001628280-26-031669
Document: a2026mayfoghornirpresent.htm	0001628280-26-031669
Document: fhtx-20260507.htm	0001628280-26-031669
Document: 0001628280-26-031669-index-headers.html	0001628280-26-031669
Document: 0001628280-26-031669-index.html	0001628280-26-031669
Document: 0001628280-26-031669.txt	0001628280-26-031669
8-K Data (Synthetic)	0001628280-26-031669

3 reports for FHTX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for FHTX — sortable, filterable
	Type				Now
May 7, 2026 4w ago	8-K NEUTRAL ★ 3/10	$4.20 $3.64	▼ −13.33%	▼ −16.47%	$3.87 (−7.86%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$5.39 $3.60	▼ −33.21%	▼ −36.38%	$3.87 (−28.20%)
Apr 21, 2026 7w ago	8-K BULLISH ★ 7/10	$5.39 $3.60	▼ −33.21%	▼ −36.38%	$3.87 (−28.20%)

US Market Status

Market Closed — Opens Thu (11h 13m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access